Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients

Conditions: Immunosuppression; Vaccine Response Impaired Interventions: Biological: Recombinant zoster vaccine adjuvanted (SHINGRIX) Sponsors: Central Adelaide Local Health Network Incorporated; National Health and Medical Research Council, Australia; University of Adelaide; Royal Prince Alfred Hospital, Sydney, Australia Not yet recruiting

https://clinicaltrials.gov/study/NCT06262776

Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials